Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.

about

Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.

Item

http://www.wikidata.org/entity/Q41016050

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.

@en

type

Item

label

Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.

@en

prefLabel

Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.

@en

P1476

Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.

@en

P2093

Karen Kinsley

http://www.w3.org/2001/XMLSchema#string

Wendy Pritchett

http://www.w3.org/2001/XMLSchema#string

P2860

Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients

Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.

Pharmacokinetic evaluation of fosaprepitant dimeglumine

Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.

Infusion phlebitis assessment measures: a systematic review.

A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.

P304

555-556

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1188/16.CJON.555-556

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27668376

http://www.w3.org/2001/XMLSchema#string

P932

5510647

http://www.w3.org/2001/XMLSchema#string